Poropatich C, Nozawa S, Rojas M, Chapman W B, Silverberg S G
Department of Pathology, George Washington University Medical Center, Washington, DC 20037.
Int J Gynecol Pathol. 1990;9(1):73-9. doi: 10.1097/00004347-199001000-00007.
The reactivity of a new monoclonal antibody (MAb), MSN-1, raised against a human endometrial cancer cell line (SNG-II), was studied in a variety of endometrial, endocervical, and ovarian carcinomas as well as normal cycling endometrium. Moderate to strong reactivity (2-3+) was seen in six of nine normal secretory endometria (67%), one of 10 normal proliferative endometria (10%), 18 of 18 endometrial adenocarcinomas (100%), 10 of 11 endometrioid ovarian adenocarcinomas (91%), seven of nine clear cell ovarian adenocarcinomas (78%), one of 12 endometrial hyperplasias without atypia (9%), two of four endometrial hyperplasias with atypia (50%), zero of five endometrial serous adenocarcinomas, two of 17 serous ovarian adenocarcinomas (12%), zero of 10 intestinal-type mucinous ovarian adenocarcinomas, and zero of nine metastatic adenocarcinomas in ovary. Endocervical adenocarcinomas showed moderate to strong staining in 75% (six of eight). It is concluded that MSN-1 can be used to confirm endometrioid/clear cell differentiation in ovarian and endometrial tumors, cannot be used to discriminate endocervical from endometrial differentiation, cannot be used to discriminate atypical hyperplasia from carcinoma, and may be useful to distinguish between atypical (premalignant) endometrial hyperplasias and those without atypia.
研究了一种针对人子宫内膜癌细胞系（SNG-II）产生的新型单克隆抗体（MAb）MSN-1，在多种子宫内膜癌、子宫颈癌和卵巢癌以及正常周期性子宫内膜中的反应性。在9例正常分泌期子宫内膜中有6例（67%）出现中度至强反应性（2-3+），10例正常增殖期子宫内膜中有1例（10%），18例子宫内膜腺癌全部（100%），11例子宫内膜样卵巢腺癌中有10例（91%），9例透明细胞卵巢腺癌中有7例（78%），12例无异型性的子宫内膜增生中有1例（9%），4例有异型性的子宫内膜增生中有2例（50%），5例子宫内膜浆液性腺癌均为阴性，17例浆液性卵巢腺癌中有2例（12%），10例肠型黏液性卵巢腺癌均为阴性，9例卵巢转移性腺癌均为阴性。子宫颈腺癌中有75%（8例中的6例）显示中度至强染色。结论是，MSN-1可用于确认卵巢和子宫内膜肿瘤中的子宫内膜样/透明细胞分化，不能用于区分子宫颈和子宫内膜分化，不能用于区分非典型增生和癌，可能有助于区分非典型（癌前）子宫内膜增生和无异型性的增生。
